Diabetes and Heart Failure: Is it Hyperglycemia or Hyperinsulinemia?
- PMID: 30963973
- DOI: 10.2174/1570161117666190408164326
Diabetes and Heart Failure: Is it Hyperglycemia or Hyperinsulinemia?
Abstract
The cardiac effects of exogenously administered insulin for the treatment of diabetes (DM) have recently attracted much attention. In particular, it has been questioned whether insulin is the appropriate treatment for patients with type 2 diabetes mellitus and heart failure. While several old and some new studies suggested that insulin treatment has beneficial effects on the heart, recent observational studies indicate associations of insulin treatment with an increased risk of developing or worsening of pre-existing heart failure and higher mortality rates. However, there is actually little evidence that the associations of insulin administration with any adverse outcomes are causal. On the other hand, insulin clearly causes weight gain and may also cause serious episodes of hypoglycemia. Moreover, excess of insulin (hyperinsulinemia), as often seen with the use of injected insulin, seems to predispose to inflammation, hypertension, dyslipidemia, atherosclerosis, heart failure, and arrhythmias. Nevertheless, it should be stressed that most of the data concerning the effects of insulin on cardiac function derive from in vitro studies with isolated animal hearts. Therefore, the relevance of the findings of such studies for humans should be considered with caution. In the present review, we summarize the existing data about the potential positive and negative effects of insulin on the heart and attempt to answer the question whether any adverse effects of insulin or the consequences of hyperglycemia are more important and may provide a better explanation of the close association of DM with heart failure.
Keywords: Diabetes; autonomic neuropathy; cardiomyopathy; diastolic dysfunction; heart failure; insulin; systolic dysfunction..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes.Prog Cardiovasc Dis. 2017 Nov-Dec;60(3):422-434. doi: 10.1016/j.pcad.2017.09.001. Epub 2017 Sep 25. Prog Cardiovasc Dis. 2017. PMID: 28958751 Review.
-
Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.Postgrad Med. 2016 Aug;128(6):609-19. doi: 10.1080/00325481.2016.1191955. Epub 2016 Jun 3. Postgrad Med. 2016. PMID: 27210018 Review.
-
Heart Failure in Type 2 Diabetes Mellitus.Circ Res. 2019 Jan 4;124(1):121-141. doi: 10.1161/CIRCRESAHA.118.311371. Circ Res. 2019. PMID: 30605420 Free PMC article. Review.
-
Insulin glulisine may cause a disease resembling insulin autoimmune syndrome: case report.Diabetes Care. 2013 Dec;36(12):e195-6. doi: 10.2337/dc13-1187. Diabetes Care. 2013. PMID: 24265369 Free PMC article. No abstract available.
-
Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.Cardiovasc Diabetol. 2019 Nov 15;18(1):156. doi: 10.1186/s12933-019-0960-8. Cardiovasc Diabetol. 2019. PMID: 31729990 Free PMC article. Clinical Trial.
Cited by
-
Risk Predictors of 3-Month and 1-Year Outcomes in Heart Failure Patients with Prior Ischemic Stroke.J Clin Med. 2022 Oct 7;11(19):5922. doi: 10.3390/jcm11195922. J Clin Med. 2022. PMID: 36233790 Free PMC article.
-
Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: The intriguing effect.J Adv Pharm Technol Res. 2020 Jul-Sep;11(3):142-147. doi: 10.4103/japtr.JAPTR_18_20. Epub 2020 Jul 14. J Adv Pharm Technol Res. 2020. PMID: 33102198 Free PMC article.
-
Insulin Receptors and Insulin Action in the Heart: The Effects of Left Ventricular Assist Devices.Biomolecules. 2022 Apr 14;12(4):578. doi: 10.3390/biom12040578. Biomolecules. 2022. PMID: 35454166 Free PMC article. Review.
-
Sudomotor dysfunction is associated with impaired left ventricular diastolic function in persons with type 2 diabetes: a cross-sectional study.J Endocrinol Invest. 2024 Apr;47(4):973-982. doi: 10.1007/s40618-023-02214-0. Epub 2023 Nov 24. J Endocrinol Invest. 2024. PMID: 37999892
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical